Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Altimmune, Inc. (NASDAQ:ALT) have been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $18.80.

A number of analysts have commented on the company. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Altimmune in a report on Thursday, August 22nd. B. Riley restated a “buy” rating and set a $20.00 target price on shares of Altimmune in a research note on Monday, August 12th. Evercore ISI upgraded shares of Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Piper Sandler restated an “overweight” rating and set a $25.00 price objective on shares of Altimmune in a research report on Friday, June 21st.

Insider Activity

In other news, Director David Drutz sold 16,011 shares of Altimmune stock in a transaction on Monday, August 19th. The shares were sold at an average price of $6.90, for a total transaction of $110,475.90. Following the transaction, the director now owns 41,958 shares in the company, valued at approximately $289,510.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ALT. North Star Investment Management Corp. bought a new stake in shares of Altimmune during the 1st quarter valued at $31,000. CANADA LIFE ASSURANCE Co bought a new stake in Altimmune during the first quarter valued at about $44,000. TFO Wealth Partners LLC purchased a new position in shares of Altimmune in the first quarter valued at about $51,000. Horizon Wealth Management LLC purchased a new position in shares of Altimmune in the second quarter valued at about $66,000. Finally, PFG Investments LLC bought a new position in shares of Altimmune in the second quarter worth about $67,000. Institutional investors own 78.05% of the company’s stock.

Altimmune Stock Down 5.0 %

Shares of ALT stock opened at $6.47 on Friday. The stock has a market cap of $458.74 million, a price-to-earnings ratio of -4.07 and a beta of 0.08. The business’s fifty day moving average is $6.68 and its 200 day moving average is $7.28. Altimmune has a twelve month low of $2.09 and a twelve month high of $14.84.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01). Altimmune had a negative return on equity of 53.09% and a negative net margin of 24,778.97%. The company had revenue of $0.01 million during the quarter. During the same quarter in the prior year, the firm earned ($0.32) EPS. Equities research analysts expect that Altimmune will post -0.54 earnings per share for the current fiscal year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.